A Study of Survival and Outcome After Stroke

Ischemic Stroke Clinical Trial

— SOS  

Official title:

The SOS Study: A Study of Survival and Outcome After Stroke

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01193569
• Other study ID #: CLP2818
• Secondary ID: CLP2818
• Status: Completed
• First received: August 31, 2010
• Last updated: April 10, 2018
• Start date: September 2010
• Est. completion date: December 22, 2016

Study information

• Verified date: April 2018
• Source: Penumbra Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The objective of this study is to determine the natural history of acute ischemic stroke from large vessel thromboembolism in the brain. The target population is a stroke cohort with a known infarct volume who presents within 8 hours from symptom onset with a NIH Stroke Scale (NIHSS) score >10 who are eligible for mechanical thrombectomy but without receiving the treatment. Functional outcome as defined by the modified Rankin Scale (mRS) of all enrolled patients will be followed for 90 days after the index event.

Description:

The objective of this observational study is to determine the natural history of acute ischemic stroke from large vessel thromboembolism in the brain. The target population is a stroke cohort with a known infarct volume who presents within 8 hours from symptom onset with a NIH Stroke Scale (NIHSS) score >10. Functional outcome as defined by the modified Rankin Scale (mRS) of all enrolled patients will be followed for 90 days after the index event. This is a prospective, single arm, multi-center trial. Up to 200 patients at up to 30 centers will be enrolled in the study. It is anticipated that up to 150 evaluable patients will be needed for analysis. The sample size estimate is based on the primary study functional outcome at 90 days as defined by a mRS of 0-2. Assuming that this observational study will have as outcome of 25% (37/150) mRS 0-2 at day 90, the expected two-sided exact binomial confidence interval is (18%, 32%). This sample size is adequate to estimate the mRS outcome of 0-2 at day 90 for the natural history of acute ischemic stroke.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 142
• Est. completion date: December 22, 2016
• Est. primary completion date: December 22, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

• From 18 to 85 years of age

• Evidence of proximal anterior circulation large vessel occlusion (TIMI 0-1/TICI 0-1)from CT Angiography. Target vessel occlusion may include the supra-clinoid segment of the ICA through the M1 segment of the MCA.

• Presented with symptoms consistent with acute ischemic stroke within 8 hours of symptom onset. Patients who presented within 3 hours must be ineligible or refractory to IV rtPA therapy.

• At time of enrollment, neurological deficit resulting in an NIH Stroke Scale (NIHSS) score > 10

• Known core infarct volume assessed by CTP, CTA or DWI scans

Exclusion Criteria:

• History of stroke in the past 3 months.

• Pre-existing neurological or psychiatric disease that could confound the study results such as a pre-stroke mRS score >1

• Known severe allergy to contrast media

• Uncontrolled hypertension (defined as systolic blood pressure >185 mmHg or diastolic blood pressure >110 mmHg)

• CT evidence of the following conditions before enrollment:

• Significant mass effect with midline shift

• Evidence of intracranial hemorrhage

• Treated with endovascular therapy for acute stroke

• Life expectancy was thought to be less than 90 days prior to stroke due to non-stroke illness

• Participation in another clinical investigation that could confound the evaluation of the study

Related Conditions & MeSH terms

• Ischemic Stroke
• Stroke

Locations

Country	Name	City	State
United Kingdom	Acute Vascular Imaging Centre, John Radcliffe Hospital, University of Oxford	Oxford

Sponsors (1)

Lead Sponsor	Collaborator
Penumbra Inc.

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of patients with a modified Rankin score of 2 or less		90 days after the procedure
Secondary	NIHSS score of 0-1 or a 10 or more points improvement		Discharge
Secondary	All cause mortality		90 days post-procedure
Secondary	Incidents of symptomatic and asymptomatic intracranial hemorrhage		90 days post-procedure